Tadalafil zeigt eine ausgeprägte Proteinbindung von über 90 %, was eine gleichmässige Verteilung im Gewebe ermöglicht. Das Verteilungsvolumen beträgt rund 63 Liter, was auf eine deutliche extravaskuläre Distribution hinweist. Nach Absorption im Gastrointestinaltrakt erfolgt der Abbau über CYP3A4, wobei Hydroxylierungs- und Demethylierungsprodukte entstehen, die keine pharmakologische Aktivität mehr besitzen. Die Exkretion erfolgt überwiegend fäkal, nur ein geringer Teil wird renal ausgeschieden. Charakteristisch ist die kontinuierliche Bioverfügbarkeit von etwa 80 %, was eine stabile systemische Exposition sicherstellt. Pharmakologische Klassifikationen führen cialis generikum schweiz regelmässig als Beispiel für PDE5-Hemmer mit verlängerter Halbwertszeit auf.

Programme atc- eric thervet

Programme ATC- Yannick LE MEUR

Sunday

Concurrent Session: Kidney Immunosuppression: CNI Minimization – Avoidance
Protocols
16h00
[129] Efficacy and Safety of Mycophenolate Mofetil (MMF)/Sirolimus (SRL) Maintenance Therapy after Calcineurin Inhibitor (CNI) Withdrawal in Renal Transplant Recipients: Final Results of the Spare-the-Nephron (STN) Trial. [130] Analysis of Allospecific T Cells in Kidney Transplant Patients on Various Immunosuppressive Protocols. [131] Cyclosporin Induces Epithelial to Mesenchymal Transition in Renal Grafts. [132] Vascular Calcineurin Inhibitor Toxicity in Early Protocol Biopsies from Human Renal Allografts. [133] Donor Marrow Infusion in Kidney Transplantation: Results of Preliminary Study. [134] Sirolimus Monotherapy in Kidney Transplantation: Results of an ITN-Sponsored Trial.
Monday

Concurrent Session: Kidney Immunosuppression: Minimization – Avoidance Protocols

16h00
[285] Extended Enrollment and Analysis of a Prospective Steroid-Free Immunosuppression Trial Supports Study Safety and Efficacy. [286] Prospective Randomized Trial of Maintenance Immunosuppression (IS) in Prednisone (P)-Free Recipients: 5-Year Results. [287] A Randomized, Open-Label Study To Compare the Efficacy and Safety of Two Different Sirolimus (SRL) Regimens with Tacrolimus (TAC) + Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients: Preliminary 2-Year Efficacy Results from the ORION Trial. [288] Long-Term Graft Survival (t½) after Rapid Discontinuation of Prednisone. [289] Successful Calcineurin-Inhibitor (CI) Discontinuation Following Early Steroid Withdrawal (ESW) in Renal Allograft Recipients; Reduced Chronic Allograft Nephropathy (CAN) and Improved Renal Function without Increased Rejection or Graft Loss. [290] A Prospective Randomized Study of Pharmacogenetic Adaptation of Tacrolimus (TAC) Treatment after Renal Transplantation.
Poster Session: Kidney Immunosuppression
17h00
[1259] A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients To Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day. [1260] NVP-AEB071 Pharmacokinetics: Effect of Metabolic Inhibition with Ketoconazole. [1261] Impact of Immunosuppressive Therapy upon Post-Transplantation Anemia: Data from the TranCept Observational Study. [1262] Cost-Effectiveness Analysis of Low Toxicity Immunosuppressive Regimens. Preliminary Results of the Quality of Life Substudy within the Symphony Study. [1263] Myfortic vs. CellCept: A Large, Single-Center Comparison. [1264] Prospective Pharmacoepidemiological Analysis of Sirolimus as Primary Immunosuppression after Kidney Transplantation in Usual Clinical Practice: Results of the ROAR™ Trial. [1265] Prospective Pharmacoepidemiological Evaluation of Sirolimus as Conversion Immunosuppression after Kidney Transplantation in Usual Clinical Practice: Results of the ROAR™ Trial. [1266] IMPDH Activity Is Correlated with the 3757T>C Polymorphism in the IMPDH Type 2 Gene in MMF Treated Kidney Transplant Patients. [1267] Immunosuppressant Regimen Based on Sirolimus Decreases Aortic Stiffness in Renal Transplant Recipients in Comparison to Cyclosporine. [1268] The Evaluation of Optimal Dose of Rituximab in ABO-Incompatible Kidney Transplantation without Splenectomy. [1269] Multi-Center Evaluation of the ARCHITECT Tacrolimus Assay. [1270] Analytical Multi-Site Evaluation of the Architect Cyclosporine Assay.
Tuesday


16h00
[LB01] A Protocol Biopsy Analysis from an NIH Multicenter Pediatric Renal Transplant Trial Reveals No Adverse Effect of Steroid Avoidance on the Histological Evolution of Chronic Graft Injury. [LB02] Donor-Derived Disease Transmission Events in the United States: A Report from the OPTN/UNOS Diseases Transmission Advisory Group (DTAG). [LB03] Prior Living Kidney Donors Who Were Subsequently Placed on the Waiting List: An Updated OPTN Analysis. [LB04] CNI Sparing in De Novo Renal Transplantation: 3-Year Results from the Symphony Study. [LB05] Discovering What the Eye Can't See: Gene Expression in Baseline Biopsies of Kidney Allografts. [LB06] ISA247: A Phase IIb Multicenter, Open Label, Concentration-Controlled Trial in De Novo Renal Transplantation.
Poster Session: Kidney Immunosuppression: CNI Minimization – Avoidance Protocols

17h00
[1524] A Randomized, Open-Label Study To Compare the Safety and Efficacy of Two Different Sirolimus (SRL) Regimens with Tacrolimus (TAC) + Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients: Preliminary 2-Year Safety Results from the ORION Trial. [1525] Sirolimus-Based Calcineurin Inhibitor-Sparing Immunotherapy, 6-Year Results. [1526] Renal Function with Enteric-Coated Mycophenolate Sodium in Combination with Reduced and Standard Tacrolimus Levels: Results of a 6-Month Comparative Study in De Novo Renal Transplant Recipients. [1527] Time-Dependent Analysis of Influence of Everolimus and CsA Blood Levels on the Risk of Acute Rejection after Renal Transplantation. [1528] Tacrolimus-MMF-Prednisone vs Everolimus-Low Dose Cyclosporine-Prednisone: 1 Year Results of a Prospective Clinical Trial. [1529] New Onset Diabetes Mellitus Was Lower in Enteric-Coated Mycophenolate Sodium Treated De Novo Renal Transplant Recipients with Reduced Tacrolimus Target Levels Than with Standard Tacrolimus Target Levels: Results of a 6-Month Randomized Study. [1530] Upper Everolimus Blood Levels with Very Low-Dose Cyclosporin in Renal Transplantation: 6-Month Results of the Everest Study. [1531] Predictors of Proteinuria Following Sirolimus Conversion: Analysis of a Large, Single Center Experience. - 05:00 PM [1532] Clinical Correlates of Glomerular Filtration Rate and Urinary Protein Excretion after Conversion from Tacrolimus to Sirolimus in Kidney Transplant Recipients. [1533] A Prospective Study of Steroid Free, Calcineurin Inhibitor Free Maintenance Immunosuppression Based on Rapamune/Myfortic in Kidney Transplantation. [1534] Tacrolimus (Tac)-Everolimus (EVL) Combination for Kidney Transplantation (KT): A Phase II Dose Comparison Randomized Pharmacokinetic (PK) Study. [1535] Concentration-Controlled Everolimus Is Effective and Well-Tolerated in Pediatric De Novo Renal Transplantation: Results at 12 Months. [1536] 6-Month Feasibility Study To Evaluate Replacement of Calcineurin Inhibitors (CNI) with Basiliximab in CNI-Intolerant Maintenance Kidney Transplant Recipients. [1537] Mycophenolic Acid (MPA) Adaptation over Time and Relationship between Trough and AUC in the Opticept Trial. [1538] Monitoring of Mycophenolic Acid Therapy in Renal Transplant Patients by Inosine-Monophosphate-Dehydrogenase (IMPDH) Activity. [1539] Three Years Outcome of Mycophenolate Mofetil Addition to Calcineurin-Inhibitor-Based Regimen in Kidney Transplant Recipients with Biopsy Proven Chronic Graft Dysfunction. [1540] Conversion from Calcineurin Inhibitor (CNI) Based Therapy to Sirolimus (SLR) Is Effective after Steroid Withdrawal (STW) in African American (AA) Patients with Late Renal Allograft Dysfunction. [1541] Predictors of Proteinuria in Renal Transplant Recipients Treated with Sirolimus. [1542] Comparison of Adverse Events (AEs) and Quality of Life of MMF and MPS in Long Term Kidney Transplant Recipients. A Prospective, Randomized Controlled Trial.
Poster Session: Kidney Immunosuppression: Steroid Minimization – Avoidance
Protocols

17h00
[1543] Long Term Outcome of Steroid Free Maintenance Immunosuppression with Sirolimus and Low Dose Cyclosporine in Primary Kidney Transplantation. [1544] Five Year Analysis of Early Steroid Withdrawal in African-American Renal Transplant Recipients. [1545] Steroid Avoidance – Good for Most but Is There a Price To Pay? [1546] Tacrolimus-Based Immunosuppression in Renal Transplantation: Two Steroid–Free Versus Standard Regimen – A 3 Year Investigator-Initiated, Observational Follow-Up of the ATLAS Trial. [1547] Efficacy and Safety of Maintenance Neoral Monotherapy Compared to Bitherapy Neoral+ MMF or AZA in Renal Transplantation: Long Term Results. [1548] Alemtuzumab Induction with Steroid Sparing Immunosuppression in High Risk Kidney Transplantation. [1549] Rapid Steroid Withdrawal in Hispanic Renal Transplant Recipients. [1550] Early Steroid Withdrawal (Day 6) after Renal Transplantation, Long-Term Results. [1551] Prospective Randomized Multicenter Trial on Steroid Withdrawal in Pediatric Renal Transplant Recipients with Stable Graft Function under Cyclosporin A (CsA) and Mycophenolate Mofetil (MMF). [1552] Long Term Follow-Up after Early Steroid Withdrawal and Calcineurin-Inhibitor Minimization in Moderate to High Immunologic Risk Renal Transplant Recipients Including ABO Incompatible and Donor-Specific Antibody (DSA). [1553] A Case-Matched, Retrospective, Single-Center Study Comparing Low-Dose Tacrolimus/Sirolimus and Tacrolimus/MMF after Renal Transplantation with Early Steroid Withdrawal after rATG Induction. [1554] Calcineurin Inhibitor (CIN) and Mycophenolic Acid (MPA) Versus CIN and Sirolimus (SLR) in Recipients with Kidney Retransplantation: Two Year Analysis. [1555] Early Steroid Withdrawal (ESW) Versus Chronic Steroid Therapy (CST) after Retransplantation in Kidney Recipients: One Year Analysis. [1556] Weight of Numbers or Scientific Merit? — An Analysis of Steroid Withdrawal Studies at the ATC, 2006-2007. [1557] Early vs Late Steroid Withdrawal (SW) in Kidney Transplantation (KT): Metaanalysis and Metaregression of Randomized Clinical Trials (RCTs). [1558] Twenty Years of HLA-Identical Live Donor Kidney Transplantation with Early Steroid Withdrawal (ESW). [1559] Is Early Protocol Biopsy Beneficial in African American (AA) Kidney Transplant Recipients on a Steroid Avoidance Protocol (SAP)? [1560] Optimizing Immunosuppression for Elderly Kidney Transplant Recipients. [1561] Efficacy of Low Dose Thymoglobulin Induction for Renal Transplantation in the Setting of Early Steroid Withdrawal. 17h00 [1562] Influence of Cyclosporine Exposure on the Pharmacokinetics of Mycophenolic Acid in
17h00 [1563] CORRETA Trial (CORticosteroid REduction with TAcrolimus): A Prospective Brazilian
Multicenter, Randomized Trial of Early Steroid Reduction vs. Regular Steroid Dosage Maintenance on a Tacrolimus (TAC – Prograf®) and Mycophenolate Mofetil (MMF) Immunosuppression (IS) Regimen in Kidney Transplant. 17h00 [1564] Steroid Avoidance in African American Patients Undergoing Kidney Transplantation.
17h00 [1565] Early Corticosteroid Discontinuation after Kidney Transplant Does Not Deteriorate Graft

Wednesday
Concurrent Session: Kidney Immunosuppression: CNI Minimization/Avoidance Protocols

10h15
[526] Opticept Trial: Efficacy and Safety of Monitored MMF in Combination with CNI in Renal Transplantation at 12 Months. [527] Comparison at One Year of Interstitial Fibrosis (IF) by Automatic Quantification in Renal Transplant Recipients with Cyclosporine (CsA) Discontinuation and Sirolimus (SRL) Introduction. [528] Effects of CNI or MMF Withdrawal on Carotid Intima Media Thickness in Renal Transplant Recipients. [529] Calcineurin Inhibitor Effects on Glucose Metabolism and Endothelial Function Following Renal Transplantation. [530] Final Renal Function Outcomes from the Spare-the-Nephron (STN) Trial: Mycophenolate Mofetil (MMF)/Sirolimus (SRL) Maintenance Therapy and CNI Withdrawal in Renal Transplant Recipients. [531] Improved Outcomes after De Novo Renal Transplantation: 2-Year Results from the Symphony Study.

Source: http://www.currenttransplant.com/Programme_YannickLEMEUR.pdf